News

Article

SABCS: Debu Tripathy Discusses Immunotherapy in Breast Cancer

Key Takeaways

  • Immunotherapy, including Keytruda, shows promise in treating triple-negative breast cancer, benefiting diverse patient groups.
  • Incremental progress in immunology is anticipated, with step-wise improvements as understanding of breast cancer pathways evolves.
SHOW MORE

Debu Tripathy, editor-in-chief of CURE magazine, recaps the first day of the San Antonio Breast Cancer Symposium - namely the advances in treating breast cancer with immunotherapy.

Debu Tripathy, editor-in-chief of CURE magazine, recaps the first day of the San Antonio Breast Cancer Symposium - namely the advances in treating breast cancer with immunotherapy.

Several studies were presented that examined how immunotherapy, such as Keytruda (pembrolizumab) in triple-negative breast cancer, could provide benefit to different groups of patients.

"We look forward to the field of immunology much more and expect to see more progress, although it's not going to be dramatic, one big fell swoop at a time," he says. "We're going to make step-wise improvements in this area as we learn more about the immunology pathways as they pertain to breast cancer."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content